Specificity and sensitivity of anti-β2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome

2007 ◽  
Vol 26 (10) ◽  
pp. 1663-1670 ◽  
Author(s):  
Virunya Parkpian ◽  
Oravan Verasertniyom ◽  
Monchand Vanichapuntu ◽  
Kitti Totemchokchyakarn ◽  
Kanokrat Nantiruj ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Features ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Lupus Anticoagulant ◽  
Anticardiolipin Antibody ◽  
Systemic Lupus ◽  
Glycoprotein I ◽  
Specificity And Sensitivity

The antiphospholipid (antibody) syndrome

2011 ◽  
pp. 343-352
Author(s):  
Alan J. Hakim ◽  
Gavin P.R. Clunie ◽  
Inam Haq
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Autoimmune Diseases ◽  
Venous Thrombosis ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Lupus Anticoagulant ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Systemic Lupus ◽  
Pregnancy Morbidity

Introduction 344 Epidemiology and pathology 345 Clinical features of antiphospholipid syndrome 346 Treatment of antiphospholipid syndrome 348 Catastrophic antiphospholipid syndrome 350 The antiphospholipid syndrome (APS) was first described in the 1980s and comprises arterial and venous thrombosis with or without pregnancy morbidity in the presence of anticardiolipin (ACL) antibodies or the lupus anticoagulant (LAC). It can be primary, or secondary to other autoimmune diseases, most commonly systemic lupus erythematosus (SLE) (...

Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus

2004 ◽  
Vol 92 (12) ◽  
pp. 1303-1311 ◽  
Author(s):  
Anthi Balitsari ◽  
John Routsias ◽  
Panayiotis G.Vlachoyiannopoulos ◽  
Clio Mavragani ◽  
Efi Bourazopoulou
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Amino Acid Position ◽  
Systemic Lupus ◽  
Multiple Antigenic Peptide ◽  
Glycoprotein I ◽  
Peptide Carrier ◽  
Intracellular Domains ◽  
Peptide Antibodies

SummaryAnti-β2glycoprotein I (anti-β2GPI) antibodies constitute the main autoantibody specificity in the sera of patients with antiphospholipid syndrome (APS). There is evidence that antiβ2GPI antibodies induce the precoagulant activity of the endothelium by cross-linking the β2 glycoprotein I (β2GPI) on the cell surface. Since β2GPI lacks intracellular domains, homology with other molecules such as CD40 that could initiate signaling, was extensively searched. A 86% homology between the amino acid position 239-245 of the CD40 and 7-13 of the β2glycoprotein was found. The CD40 peptide corresponding to amino acids 239-245 of the CD40 molecule was synthesized and coupled to a multiple antigenic peptide carrier. Antibodies to CD40 peptide were found in 61.5% APS patients (n=39), in 72.7% of systemic lupus erythematosus (SLE) positive for anti β2GPI antibodies (n=11) and 31.6% of SLE negative for antiβ2GPI antibodies (n=19), but not in rheumatoid arthritis patients (n=28) or controls (n=36). Antibodies to CD40 peptide were associated with arterial thrombosis and/or brain microinfarcts. Affinity purified anti-CD40 peptide antibodies as well as affinity purified anti-β2GPI antibodies recognized both, the β2GPI and the CD40 peptide. The specificity of this recognition was confirmed with homologous and heterologous inhibition experiments. Confocal microscopy experiments demonstrated this cross-recognition of CD40 and β2GPI molecules, by the purified anti-CD40 peptide antibodies, at the protein level. Thus, antibodies reacting with the β2GPI can react and potentially activate different cells which express CD40 molecules at their surface.

Systemic lupus erytherymatosus: an interdisciplinary approach to the diagnosis

2016 ◽  
Vol 19 (3) ◽  
pp. 141-147
Author(s):  
M. M Tlish ◽  
Zhanna Yu. Naatyzh ◽  
N. L Sycheva ◽  
T. G Kuznetsova ◽  
G. A Irizelyan ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Lupus Anticoagulant ◽  
Prognostic Significance ◽  
Anticardiolipin Antibody ◽  
Interdisciplinary Approach ◽  
Systemic Lupus ◽  
Cardiolipin Antibodies ◽  
Definition Of ◽  
Clinical Cases

Diagnosis of systemic lupus erythematosus presents certain difficulties up to now. Due to the prognostic significance of the disease and the need to early pathogenetic treatment clinical cases of SLE are described. Questions of modern differential diagnosis are reviewed. If skin changes are presented a positive test for antinuclear antibodies helps to detect SLE timely. 4 clinical cases of women with systemic lupus erythematosus are presented. Diagnostics required comprehensive examination with histopathological and immunological studies: blood test antinuclear factor on HEp-2 cells with the definition of lupus anticoagulant in blood plasma, rheumatoid factor, anticardiolipin antibody IgG and IgM, double stranded DNA, antinuclear antibody IgG, auto antibodies to IgG AMA-M2 (immunoblott), cardiolipin antibodies and lupus anticoagulant.

scholarly journals Distribution and Clinical Significance of Lupus Anticoagulant and Anticardiolipin Antibody in 349 Patients with Systemic Lupus Erythematosus.

1992 ◽  
Vol 31 (2) ◽  
pp. 194-199 ◽  
Author(s):  
Chiho NINOMIYA ◽  
Osamu Taniguchi ◽  
Toshihiko KATO ◽  
Takao HIRANO ◽  
Hiroshi HASHIMOTO ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Significance ◽  
Lupus Erythematosus ◽  
Lupus Anticoagulant ◽  
Anticardiolipin Antibody ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document